Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;47:4791–4806.

Article  Google Scholar 

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–9.

Article  CAS  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

Article  Google Scholar 

Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;1:1208–11.

Article  CAS  Google Scholar 

Thompson G, Parhofer KG. Current role of lipoprotein apheresis. Curr Atheroscler Rep. 2019;21:26.

Article  Google Scholar 

Parhofer KG, Von Stritzky B, Pietschmann N, Dorn C, Paar D. PEARL: a non-interventional study of real-world alirocumab use in German clinical practice. Drugs - Real World Outcomes. 2019;6(3):115–23. 

Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37:3588–95.

Article  CAS  Google Scholar 

Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, et al. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol. 2018;25:1843–51.

Article  Google Scholar 

Otto C, Geiss HC, Empen K, Parhofer KG. Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis. 2004;174:151–6.

Article  CAS  Google Scholar 

Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, Eriksson M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010;21:492–8.

Article  CAS  Google Scholar 

Winters JL. Lipid apheresis, indications, and principles. J Clin Apher. 2011;26:269–75.

Article  Google Scholar 

GBA GB-A. Apheresis for elevated LDL-cholesterol. 2003. https://www.g-ba.de/downloads/39-261-64/2003-07-09-bub-apheresen.pdf. Accessed 23 Jan 2023.

GBA GB-A. Apheresis for elevated lipoprotein(a). 2013. https://www.g-ba.de/downloads/39-261-1632/2013-01-17_MVV-RL-DokIndApherese_BAnz.pdf. Accessed 23 Jan 2023.

Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:133–40.

Article  Google Scholar 

Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247–55.

Article  CAS  Google Scholar 

Waldmann E, Parhofer KG. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology. 2019;51:227–32.

Article  CAS  Google Scholar 

Pokrovsky SN, Adamova I, Afanasieva OY, Benevolenskaya GF. Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study. Artif Organs. 1991;15:136–40.

Article  CAS  Google Scholar 

Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998;82:1489–95.

Article  CAS  Google Scholar 

Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811–6.

Article  CAS  Google Scholar 

Safarova MS, Ezhov MV, Afanasieva OI, Matchin YG, Atanesyan RV, Adamova IY, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14:93–9.

Article  CAS  Google Scholar 

Safarova MS, Nugent AK, Gorby L, Dutton JA, Thompson WJ, Moriarty PM. Effect of lipoprotein apheresis on progression of carotid intima-media thickness in patients with severe hypercholesterolemia. Am J Cardiol. 2022;177:22–7.

Khan TZ, Hsu LY, Arai AE, Rhodes S, Pottle A, Wage R, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. Eur Heart J. 2017;38:1561–9. Study shows improvement in mycardial perfusion reserve (MRI) with 3 months of apheresis in patients with elevated lipoprotein(a) using a randomized, sham-apheresis controlled setting.

Article  Google Scholar 

Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229–39.

CAS  Google Scholar 

Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567–76.

Article  CAS  Google Scholar 

Rosada A, Kassner U, Vogt A, Willhauck M, Parhofer K, Steinhagen-Thiessen E. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs. 2014;38:135–41.

Article  CAS  Google Scholar 

Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019;13:894–900.

Article  Google Scholar 

Ezhov MV, Afanasieva OI, Il’ina LN, Safarova MS, Adamova IY, Matchin YG, et al. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis. Atheroscler Suppl. 2017;30:187–92.

Article  Google Scholar 

Bigazzi F, Sbrana F, Berretti D, Maria Grazia Z, Zambon S, Fabris A, et al. Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfus Apher Sci. 2018;57:661–4.

Article  Google Scholar 

Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein (a). J Lipid Res. 2016;57:1751–7.

Article  CAS  Google Scholar 

Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, et al. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on. Clin Res Cardiol Suppl. 2017;12:44–9. Large registry based data set on the use of apheresis in real world setting in Germany.

Article  CAS  Google Scholar